Ligand Pharmaceuticals | LGND - Ebit

Stock Price
203.61
Daily Change
4.02 2.01%
Monthly
-2.19%
Yearly
104.82%
Q2 Forecast
193.58

Ligand Pharmaceuticals reported $158.89M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Enviri Corporation USD -35.28M 61.58M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Intrexon USD -26.3M 2.91M Jun/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
MacroGenics USD -12.1M 32.26M Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Pacira USD 3.19M 9.96M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Veracyte USD 24.63M 1.52M Dec/2025